Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT02416908
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Epigenetic Reprogramming in Relapse AML
- Conditions
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Michael Burke
- Target Recruit Count
- 3
- Registration Number
- NCT02412475
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02400281
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT02392793
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 420
- Registration Number
- NCT02375204
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 9
- Registration Number
- NCT02331134
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 40
- Registration Number
- NCT02298283
- Locations
- 🇫🇷
CH Sud Francilien, Corbeil-Essonnes, France
🇫🇷Hôpital André Mignot, Le Chesnay, France
🇫🇷Centre Léon Bérard, Lyon, France
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 23
- Registration Number
- NCT02282514
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Azacytidine Plus FLAG for Relapsed or Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- King Fahad Medical City
- Target Recruit Count
- 37
- Registration Number
- NCT02275663
- Locations
- 🇸🇦
King Fahad Medical City, Riyadh, Saudi Arabia
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2023-04-07
- Target Recruit Count
- 20
- Registration Number
- NCT02231879
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.